drugset / Trial / NCT06420440

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

NCT06420440 ↗

Phase 2 Recruiting 160 enrolled Chen Xiaoping
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.

Timeline

Start
2024-06-01
Primary completion
2026-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous